Esperion Therapeutics (ESPR) Q1 2025 Earnings
Esperion Therapeutics reported Q1 2025 revenue of $65.0M (-52.8% YoY), beat analyst consensus of $61.2M by $3.8M. Diluted EPS came in at $-0.21, missed the $-0.18 consensus by $0.03.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Esperion Therapeutics's Q1 2025 earnings report.
Esperion Therapeutics (ESPR) reported Q1 2025 earnings on May 6, 2025 before market open.
Esperion Therapeutics reported revenue of $65.0M and diluted EPS of $-0.21 for Q1 2025.
Revenue beat the consensus estimate of $61.2M by $3.8M. EPS missed the consensus estimate of $-0.18 by $0.03.
Compared to the same quarter a year prior, revenue declined 52.8% from $137.7M a year earlier.
You can read the 10-Q periodic report (0001628280-25-023498) directly on SEC EDGAR. The filing index links above go to sec.gov.